Alzheimer s & Dementia · 2021 · 42 citations · 33 references
PharmacyPharmacokineticsPharmacologyDrug DesignDrug DiscoveryPharmacokinetic ModelingModel EvaluationNeurodegenerative Disease PharmacologyPharmacokinetics Of Monoclonal AntibodiesQuantitative Systems PharmacologyReceptor ModelingSystems Pharmacology ModelingAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid Beta PlaquesAmyloid Beta-targeted TherapyBeta Secretase InhibitionModel-based Drug Efficacy AnalysisPlaque ReductionQuantitative Pharmacology
INTRODUCTION: Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) model for seven therapeutics: aducanumab, crenezumab, solanezumab, bapineuzumab, elenbecestat, verubecestat, and semagacestat. METHODS: Ordinary differential equations were used to model the production, transport, and aggregation of Aβ; pharmacology of the drugs; and their impact on plaque. RESULTS: The calibrated model predicts that endogenous plaque turnover is slow, with an estimated half-life of 2.75 years. This is likely why beta-secretase inhibitors have a smaller effect on plaque reduction. Of the mechanisms tested, the model predicts binding to plaque and inducing antibody-dependent cellular phagocytosis is the best approach for plaque reduction. DISCUSSION: A QSP model can provide novel insights to clinical results. Our model explains the results of clinical trials and provides guidance for future therapeutic development.
33
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Kwasi G. Mawuenyega, Wendy Sigurdson, Vitaliy Ovod et al. · Science · 2010 · 2.1K citations · Full text
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17